Barclays PLC An2 Therapeutics, Inc. Transaction History

Barclays PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.78 - $21.53 $44,257 - $342,757	-15,920 Reduced 35.99%	28,318 $92,000
Q4 2023 Feb 15, 2024	BUY	$13.92 - $21.0 $571,666 - $862,428	41,068 Added 1295.52%	44,238 $907,000
Q3 2023 Nov 07, 2023	SELL	$7.58 - $16.08 $181,192 - $384,376	-23,904 Reduced 88.29%	3,170 $51,000
Q2 2023 Aug 03, 2023	SELL	$5.06 - $9.91 $28,836 - $56,477	-5,699 Reduced 17.39%	27,074 $230,000
Q1 2023 May 04, 2023	BUY	$7.94 - $15.6 $21,557 - $42,354	2,715 Added 9.03%	32,773 $323,000
Q4 2022 Feb 13, 2023	BUY	$8.51 - $19.69 $23,657 - $54,738	2,780 Added 10.19%	30,058 $286,000
Q3 2022 Nov 03, 2022	BUY	$7.61 - $22.29 $170,387 - $499,073	22,390 Added 458.06%	27,278 $475,000
Q2 2022 Aug 12, 2022	SELL	$7.7 - $18.82 $102,656 - $250,908	-13,332 Reduced 73.17%	4,888 $38,000
Q1 2022 May 16, 2022	BUY	$15.0 - $15.4 $273,300 - $280,588	18,220 New	18,220 $275,000

13.5M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $20.8M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.